Stock Events

Stock Events

Belite Bio

$144.74

8

+$0.00+0%Wednesday 00:00

Statistics

Day High

144.74

Day Low

144.74

52W High

176.26

52W Low

144.74

Volume

17

Avg. Volume

-

Mkt Cap

5.83B

P/E Ratio

-

Dividend Yield

-

Dividend

-

Financials

-Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

0Revenue

-77.61MNet Income

Analyst Ratings

$251.60Average Price Target

The highest estimate is ⁦303.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BLTE.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a leading biotech firm focusing on creating transformative medicines for serious diseases, directly competing with Belite Bio's focus on novel therapeutics.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, making it a direct competitor in the biotech industry, particularly in areas overlapping with Belite Bio's therapeutic targets.

Biogen focuses on neurodegenerative diseases, directly competing with Belite Bio's efforts in similar therapeutic areas.

Gilead Sciences

Gilead Sciences' strong presence in antiviral and oncology treatments positions it as a competitor to Belite Bio, especially in overlapping disease areas.

Amgen's broad focus on innovative human therapeutics makes it a competitor across several of Belite Bio's interest areas, particularly in biologics.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals' work on RNA interference (RNAi) therapeutics for genetic diseases competes with Belite Bio's novel treatment approaches.

Biomarin Pharmaceutical

BioMarin Pharmaceutical's focus on rare genetic diseases places it in direct competition with Belite Bio, especially in markets targeting niche patient populations.

Novartis is a global healthcare company with a wide range of pharmaceuticals that compete across multiple therapeutic areas, including those targeted by Belite Bio.

Pfizer's extensive portfolio in healthcare and pharmaceuticals, including investments in biotechnology and innovation, makes it a broad competitor to Belite Bio.

About

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Show More

CEO

ISIN

US07782B1044

Listings

0 Comments

Share your thoughts

FAQs

What is Belite Bio stock price today?▼

The current price of BLTE.BOATS is $144.74 USD — it has increased by +0% in the past 24 hours. Watch Belite Bio stock price performance more closely on the chart.

What is Belite Bio stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Belite Bio stocks are traded under the ticker BLTE.BOATS.

What is Belite Bio market cap?▼

Today Belite Bio has the market capitalization of 5.83B

What is Belite Bio revenue for the last year?▼

Belite Bio revenue for the last year amounts to 0 USD.

What is Belite Bio net income for the last year?▼

BLTE.BOATS net income for the last year is -77.61M USD.

In which sector is Belite Bio located?▼

Belite Bio operates in the Other sector.

When did Belite Bio complete a stock split?▼

Belite Bio has not had any recent stock splits.